Last reviewed · How we verify
CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)
The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.
Details
| Lead sponsor | Fujian Medical University |
|---|---|
| Phase | PHASE2, PHASE3 |
| Status | UNKNOWN |
| Enrolment | 20 |
| Start date | Fri Aug 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Relapsed/Refractory AML
Interventions
- CD123/CLL1 CAR-T Cells
Countries
China